LumiraDx leveraged actively controlled microfluidic technology to provide accessible diagnostic solutions at the point of care. The company pursued a platform consolidation strategy, particularly in European markets like the UK and Germany, expanding its installed base of diagnostic instruments and test menu. The acquisition by Roche positioned the technology within a major global diagnostics and pharmaceutical conglomerate.
Cyborg Score Rationale
LumiraDx ceased to be an independent public company in January 2024 following its delisting from Nasdaq and acquisition agreement with Roche. Performance metrics and forward-looking thesis are no longer applicable as a standalone entity.
Top Insights
Delisted from Nasdaq in January 2024 following agreement to sell core platform to Roche
Generated $254.5 million in full-year 2022 revenue before acquisition
Expanded installed base by 1,500+ platform instruments primarily in European markets in 2022
Developed portfolio of 30+ assays spanning infectious disease, cardiovascular, diabetes, and coagulation testing